新型氟喹诺酮类药物ABT-492对从鼻窦炎患者上颌窦穿刺标本中分离出的155种需氧菌和171种厌氧菌的体外活性。
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
作者信息
Goldstein Ellie J C, Citron Diane M, Merriam C Vreni, Warren Yumi A, Tyrrell Kerin L, Fernandez Helen T
机构信息
RM Alden Research Laboratory, Santa Monica, California 90404, USA.
出版信息
Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11. doi: 10.1128/AAC.47.9.3008-3011.2003.
Abstract
ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015. It was four- to sixfold more active than other fluoroquinolones, including against levofloxacin-resistant strains of S. pneumoniae, methicillin-resistant Staphylococcus aureus, and Prevotella species.
摘要
ABT - 492对所测试的全部326株需氧和厌氧鼻窦穿刺分离菌株均表现出优异的体外活性，其最低抑菌浓度（以微克/毫升计）能抑制90%的测试分离菌株，具体如下：流感嗜血杆菌，0.001；卡他莫拉菌，0.008；肺炎链球菌，0.015。它比其他氟喹诺酮类药物活性高4至6倍，包括对耐左氧氟沙星的肺炎链球菌、耐甲氧西林金黄色葡萄球菌和普雷沃菌属菌株。
相似文献
1
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.新型氟喹诺酮类药物ABT-492对从鼻窦炎患者上颌窦穿刺标本中分离出的155种需氧菌和171种厌氧菌的体外活性。
Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11. doi: 10.1128/AAC.47.9.3008-3011.2003.
2
In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.新型酮内酯类药物ABT-773对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧和厌氧病原体的体外活性。
Antimicrob Agents Chemother. 2001 Aug;45(8):2363-7. doi: 10.1128/AAC.45.8.2363-2367.2001.
3
In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Diagn Microbiol Infect Dis. 2002 Feb;42(2):113-8. doi: 10.1016/s0732-8893(01)00341-8.
4
Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis.阿莫西林-克拉维酸对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧菌和厌氧菌的体外比较活性。
Antimicrob Agents Chemother. 1999 Mar;43(3):705-7. doi: 10.1128/AAC.43.3.705.
5
In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.替利霉素及10种口服药物对从鼻窦炎患者上颌窦穿刺标本中分离出的需氧和厌氧病原体的体外活性。
Antimicrob Agents Chemother. 2003 Jun;47(6):1963-7. doi: 10.1128/AAC.47.6.1963-1967.2003.
6
In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.DV-7751a的体外评估，一种对革兰氏阳性需氧菌和厌氧菌具有增强活性谱的新型氟喹诺酮类药物。
Antimicrob Agents Chemother. 1995 Jul;39(7):1636-42. doi: 10.1128/AAC.39.7.1636.
7
In vitro activity of BAY 12-8039, a new fluoroquinolone.新型氟喹诺酮类药物BAY 12 - 8039的体外活性
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
8
The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.新型氟喹诺酮类药物托氟沙星与环丙沙星和替马沙星的体外活性比较。
J Antimicrob Chemother. 1991 Nov;28(5):719-25. doi: 10.1093/jac/28.5.719.
9
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.新型8-甲氧基喹诺酮类药物Bay 12-8039与其他11种口服抗菌药物对从人类和动物咬伤伤口皮肤及软组织感染中分离出的390株需氧菌和厌氧菌的体外活性比较。
Antimicrob Agents Chemother. 1997 Jul;41(7):1552-7. doi: 10.1128/AAC.41.7.1552.
10
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.阿奇霉素、拜耳Y 3118、左氧氟沙星、司帕沙星及其他11种口服抗菌剂对194株需氧和厌氧咬伤伤口分离菌株的体外比较活性
Antimicrob Agents Chemother. 1995 May;39(5):1097-100. doi: 10.1128/AAC.39.5.1097.
引用本文的文献
1
Strategic re-engineering of antibiotics.抗生素的战略重组
Nat Rev Bioeng. 2025 Mar;3(3):213-229. doi: 10.1038/s44222-024-00250-w. Epub 2024 Oct 15.
2
Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.两项急性细菌性皮肤和皮肤结构感染 3 期研究中分离的氟喹诺酮敏感和不敏感金黄色葡萄球菌分离株的达托霉素活性和微生物学应答。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00772-17. Print 2017 Sep.
3
Delafloxacin: design, development and potential place in therapy.德拉氟沙星：设计、研发及在治疗中的潜在地位。
Drug Des Devel Ther. 2017 Mar 20;11:881-891. doi: 10.2147/DDDT.S106071. eCollection 2017.
4
Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.2014年达氟沙星对来自美国和欧洲的当代细菌病原体的活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02609-16. Print 2017 Apr.
5
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.针对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌分离株检测的德拉氟沙星的体外活性
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.
6
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.新型氟喹诺酮类药物ABT-492与其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性比较
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
本文引用的文献
1
Widespread use of fluoroquinolones versus emerging resistance in pneumococci.氟喹诺酮类药物的广泛使用与肺炎球菌新出现的耐药性
Clin Infect Dis. 2002 Dec 15;35(12):1505-11. doi: 10.1086/344768. Epub 2002 Dec 4.
2
Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults.与成人慢性细菌性上颌窦炎相关的细菌学发现。
Clin Infect Dis. 2002 Aug 15;35(4):428-33. doi: 10.1086/341899. Epub 2002 Jul 24.
3
Anaerobic bacteria in upper respiratory tract and other head and neck infections.上呼吸道及其他头颈部感染中的厌氧菌
Ann Otol Rhinol Laryngol. 2002 May;111(5 Pt 1):430-40. doi: 10.1177/000348940211100508.
4
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.自1994 - 1995年以来美国肺炎链球菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 2002 Mar;46(3):680-8. doi: 10.1128/AAC.46.3.680-688.2002.
5
Emergence of penicillin-nonsusceptible Streptococcus pneumoniae invasive clones in Canada.加拿大青霉素不敏感肺炎链球菌侵袭性克隆株的出现。
J Clin Microbiol. 2002 Jan;40(1):68-74. doi: 10.1128/JCM.40.1.68-74.2002.
6
Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.肺炎链球菌对氟喹诺酮类药物的耐药性增加：2000年香港多中心研究结果
J Antimicrob Chemother. 2001 Nov;48(5):659-65. doi: 10.1093/jac/48.5.659.
7
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.与左氧氟沙星治疗相关的耐氟喹诺酮肺炎链球菌
J Infect Dis. 2001 Sep 15;184(6):794-8. doi: 10.1086/323086. Epub 2001 Aug 9.
8
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership.急性细菌性鼻窦炎抗菌治疗指南。鼻窦与过敏健康合作组织。
Otolaryngol Head Neck Surg. 2000 Jul;123(1 Pt 2):5-31.
9
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.新合成喹诺酮WQ-3034、左氧氟沙星、司帕沙星和环丙沙星对结核分枝杆菌和鸟分枝杆菌复合体的抗菌活性比较
Antimicrob Agents Chemother. 2000 Feb;44(2):283-6. doi: 10.1128/AAC.44.2.283-286.2000.
10
Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.肺炎链球菌、流感嗜血杆菌和卡他莫拉菌分离株对26种抗菌药物的敏感性调查：一项美国前瞻性研究。
Antimicrob Agents Chemother. 1999 Nov;43(11):2612-23. doi: 10.1128/AAC.43.11.2612.
Zotero 插件